Nous-209 neoantigen vaccine for cancer prevention in Lynch syndrome carriers: a phase 1b/2 trial
D’Alise et al, 2026 Nature Medicine Published
D’Alise et al, 2026 Nature Medicine Published
Lynch Syndrome (LS) is a common hereditary condition that significantly increases the lifetime risk of developing multiple cancers NOUS-209 is an off-the-shelf cancer immunotherapy designed to [...]
Nouscom is a private oncology company developing next generation immunotherapies, founded in 2015 by an experienced management team that has worked together for many years in previous successful enterprises. Nouscom’s proprietary technology platform harnesses the full power of the immune response by combining viral vectored genetic vaccines based on neoantigens with other immunomodulators.
